25 results on '"Kamakshi R. Zeidler"'
Search Results
2. A Multicenter, Randomized, Double-Blind, Split-Body Clinical Trial Evaluating the Efficacy and Outcomes of a Topical Product Pre and Post Aesthetic Surgical Body Procedures
- Author
-
Laurie A Casas, R Brannon Claytor, Kamakshi R Zeidler, Sachin M Shridharani, Steven R Cohen, Julie J Khanna, Daniel J Gould, Essie K Yates, Shantel Lultschik, Michaela Bell, and Alan D Widgerow
- Subjects
Surgery ,RD1-811 - Abstract
Abstract BackgroundSkin preconditioning prior to and following procedures, has previously been demonstrated to hasten and optimize healing, and decrease the symptoms and signs associated with invasive surgery. These trials involved the use of multiple topical products. In an effort to control costs and to increase patient compliance, a single surgical product was developed, with actives aimed at decreasing swelling, bruising, induration, and internal fibrous banding. ObjectivesThis multi-center trial was designed to measure the efficacy of this single product in these mentioned parameters. MethodsA double-blind, randomized, split body, clinical study was undertaken in 29 patients involving 38 surgical procedures. Assessments included photography, biopsies, ultrasound imaging, and blinded investigator and participant assessments. ResultsDifferentiated results between test comparator sides became apparent at postop day 10-14 (as previously observed). Thus, blinded investigator and participant assessment scores demonstrated statistical significance exclusive to the test product side at postop day 10-14 for ecchymoses and then extending to skin discoloration, edema, induration and subcutaneous fibrous banding, at weeks 3, 4, 6, and 12. Ultrasound evaluation confirmed the earlier dissolution of fibrous banding on the test side in the subcutaneous tissue at the 3-6-week postop period. In addition, biopsies assessing the pre-conditioned period prior to surgery confirmed that the topical test product stimulated a remodeled extracellular matrix without comparative changes on the opposite side. ConclusionsA single peri-surgical product designed for the use with invasive surgery produced significant differences in ecchymosis, skin discoloration, edema, induration and ongoing resolution of fibrous banding over many weeks. This study validation provides an additional adjunct to surgical procedures. Level of Evidence: 2
- Published
- 2022
- Full Text
- View/download PDF
3. Results of XPAND II
- Author
-
Amy S. Colwell, Laura A. Sudarsky, Kamakshi R. Zeidler, James Appel, Kerry A. Morrison, John Castle, Jeffrey A. Ascherman, Tracey Stokes, Khashayar Mohebali, and Yoon S. Chun
- Subjects
medicine.medical_specialty ,business.industry ,Breast surgery ,medicine.medical_treatment ,030230 surgery ,law.invention ,Surgery ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Randomized controlled trial ,law ,030220 oncology & carcinogenesis ,Breast implant ,medicine ,Clinical endpoint ,Breast reconstruction ,Prospective cohort study ,business - Abstract
Background XPAND II was a prospective, multicenter, single-arm, open-label, continued-access study designed to confirm the results from the XPAND study, a multicenter, prospective, randomized study for breast reconstruction. The AeroForm device received clearance from the U.S. Food and Drug Administration in December 2016 based on the results of the pivotal XPAND trial, which compared the AeroForm to saline expanders. Methods Fifty women were treated in the XPAND II study and implanted with the AeroForm device (86 devices). The study endpoint was successful completion of the second-stage surgery, and secondary endpoints were days to complete expansion and reconstruction, and patient/physician satisfaction. Following implantation, women were administered 10-cc doses of carbon dioxide at home up to three times daily. When adequate expansion was achieved, the expanders were exchanged for standard breast implants. Results The primary endpoint (successful exchange to standard breast implant, precluding non-device-related failures) is 100 percent. All-cause interim success is 95 percent, with three subjects (four breasts) failing primary exchange because of non-device-related reasons. Median time to complete expansion was 21 days (range, 5 to 117 days). Median time to complete the reconstruction was 112 days (range, 55 to 329 days). Ninety-six percent of the subjects were very or moderately satisfied with the AeroForm expansion process. Conclusions Results of the XPAND II continued access study confirm and improve on previous results from the randomized trial (XPAND). These results validate that the AeroForm patient-controlled, needle-free carbon dioxide tissue expander is safe and effective for two-stage breast reconstruction. Clinical question/level of evidence Therapeutic, IV.
- Published
- 2020
4. Maintaining Upper Pole Fullness: Auto-augmentation Mastopexy with Soft Tissue Support Matrix and Lipofilling
- Author
-
Kamakshi R. Zeidler and R. Laurence Berkowitz
- Subjects
medicine.medical_specialty ,Sling (implant) ,business.industry ,medicine.medical_treatment ,Pectoralis major muscle ,Lumpectomy ,Soft tissue ,Mastopexy ,medicine.disease ,Surgery ,Breast cancer ,medicine ,Breast reduction ,Implant ,business - Abstract
Desired outcomes of mastopexy include enhanced breast projection, corrected ptosis, prevention of bottoming out, minimal scarring, and durable upper-pole fullness. Consistently providing and maintaining optimal breast shape, particularly upper-pole fullness, is the greatest challenge in mastopexy procedures. Auto-augmentation mastopexy is an evolving option for patients who want improved breast shape without the use of an implant. This technique can correct ptosis while increasing the projection and apparent volume of the breast, and provides a more durable result with less tension on scars compared to dermal reshaping. However, even with advanced techniques, such as the use of a pectoralis sling to support the auto-augmentation segment, optimizing breast projection and upper-pole fullness and preventing bottoming out have remained challenging. To further increase the durability of upper pole fullness following mastopexy, the author developed a modification of existing techniques using synthetic or biologic soft tissue support matrix in place of a pectoralis sling. In this three-part technique, an inferior dermaglandular flap is raised and secured to the pectoralis major muscle with a belt of matrix, followed by lipofilling to maintain upper pole stability and fullness. Using this technique, the author has achieved excellent and durable aesthetic results for implant-free augmentation, correction of breast asymmetry, and volume reduction in patients without prior surgery, following breast implant removal, or after lumpectomy for breast cancer.
- Published
- 2020
5. Ten-year Core Study Data for Sientra’s Food and Drug Administration–Approved Round and Shaped Breast Implants with Cohesive Silicone Gel
- Author
-
Jennifer L. Harrington, Rosalyn C d'Incelli, Kamakshi R. Zeidler, W. Grant Stevens, M. Bradley Calobrace, and Kaveh Alizadeh
- Subjects
Adult ,Reoperation ,Breast implantation ,Surface Properties ,Breast Implants ,Breast surgery ,medicine.medical_treatment ,Dentistry ,030230 surgery ,Prosthesis Design ,law.invention ,Silicone Gels ,Food and drug administration ,03 medical and health sciences ,chemistry.chemical_compound ,Postoperative Complications ,0302 clinical medicine ,Silicone ,law ,Implant Capsular Contracture ,Premarket Approval ,Humans ,Medicine ,Breast ,Prospective Studies ,Breast Implantation ,United States Food and Drug Administration ,business.industry ,technology, industry, and agriculture ,Middle Aged ,United States ,chemistry ,Multicenter study ,Patient Satisfaction ,030220 oncology & carcinogenesis ,Breast implant ,Lymphoma, Large-Cell, Anaplastic ,Female ,Surgery ,business - Abstract
In March 2012, the United States Food and Drug Administration approved Sientra's application for premarket approval of its portfolio of round and shaped silicone gel breast implants based on data from the largest silicone gel breast implant study to date. This article presents the results of Sientra's Core Study at the conclusion of 10 years.The Sientra Core Study was a 10-year, open-label, prospective, multicenter clinical study designed to assess the safety and effectiveness of Sientra's breast implants in augmentation and reconstruction. A total of 1,788 patients (3,506 implants) were enrolled, including 1,116 primary augmentation, 363 revision-augmentation, 225 primary reconstruction, and 84 revision-reconstruction.Across all cohorts, the rate of rupture by patient was 8.6%, the rate of Baker grade III/IV capsular contracture was 13.5%, and the rate of reoperation was 31.5%. The rate of capsular contracture was statistically significantly lower for textured devices [9.0%; 95% confidence interval (CI), 7.0-11.5%] compared with smooth devices (17.5%; 95% CI, 14.9-20.4%). There were no cases of breast implant-associated anaplastic large cell lymphoma. Primary reasons for reoperations included capsular contracture (18.8%), and style/size change (19.3%), with over 50% of the reoperations due to cosmetic reasons.The 10-year results of Sientra's Core Study support a comprehensive safety and effectiveness profile of Sientra's portfolio of round and shaped breast implants.
- Published
- 2018
6. Carbon Dioxide–Based versus Saline Tissue Expansion for Breast Reconstruction
- Author
-
Amy S. Colwell, James Appel, Debra Johnson, Yoon S. Chun, John Castle, Kerry A. Morrison, Berkowitz Rl, Kamakshi R. Zeidler, Khashayar Mohebali, and Jeffrey A. Ascherman
- Subjects
Insufflation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Investigational device exemption ,030230 surgery ,Surgery ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Bolus (medicine) ,Randomized controlled trial ,law ,030220 oncology & carcinogenesis ,medicine ,Adverse effect ,business ,Breast reconstruction ,Saline ,Tissue expansion - Abstract
Background AeroForm is a new type of remote-controlled, needle-free, carbon dioxide-based expander involving a potentially faster method of tissue expansion. Results are presented here from the AirXpanders Patient Activated Controlled Tissue Expander pivotal trial comparing AeroForm to saline tissue expanders. Methods Women undergoing two-stage breast reconstruction were randomized at 17 U.S. sites in this U.S. Food and Drug Administration-approved investigational device exemption trial. Expansion in the investigational arm was performed by the patient in 10-cc increments up to 30 cc/day of carbon dioxide and in the control arm by the physician with periodic bolus injections of saline. Safety endpoints, expansion and reconstruction times, pain, and satisfaction were assessed. Results One hundred fifty women were treated: 98 with carbon dioxide expanders (n = 168) and 52 with saline expanders (n = 88). The treatment success rate (all breasts exchanged successfully excluding non-device-related failures) was 96.1 percent for carbon dioxide and 98.8 percent for saline. Median time to full expansion and completion of the second-stage operation was 21.0 and 108.5 days (carbon dioxide) versus 46.0 and 136.5 days (saline), respectively, with a similar rate of overall complications. Ease of use for the carbon dioxide expander was rated high by patients (98 percent) and physicians (90 percent). Conclusions The AirXpanders Patient Activated Controlled Tissue Expander trial results demonstrate that a carbon dioxide-based expander is an effective method of tissue expansion with a similar overall adverse event rate compared to saline expanders, and provides a more convenient and expedient expansion. Clinical question/level of evidence Therapeutic, I.
- Published
- 2016
7. PRP and Microneedling in Aesthetic Medicine
- Author
-
Jeanette M. Black, DiAnne S. Davis, Jeffrey A. Rapaport, Brenda L. Pellicane, Chatchadaporn Chunharas, Naissan O. Wesley, Lisa Donofrio, Gary Goldenberg, Brian J. Abittan, Matthias Aust, Mitchel P. Goldman, Sarah G Versteeg, Tina S. Alster, Peter W Hashim, Tatjana Pavicic, Amelia K. Hausauer, R. Lawrence Berkowitz, Aditya K. Gupta, Kamakshi R. Zeidler, Douglas C. Wu, and Derek H. Jones
- Subjects
business.industry ,Aesthetics ,Medicine ,Aesthetic medicine ,business - Published
- 2019
8. Sientra AlloX2 Short-Term Case Study, Surgical Pearls, and Roundtable Discussion
- Author
-
Troy A. Pittman, Peter J. Capizzi, and Kamakshi R. Zeidler
- Subjects
medicine.medical_specialty ,Standard of care ,Breast Implants ,Periprosthetic ,Breast Neoplasms ,030230 surgery ,Prosthesis Design ,Postoperative management ,03 medical and health sciences ,0302 clinical medicine ,Breast tissue expander ,Postoperative Complications ,Medicine ,Humans ,Sampling (medicine) ,Breast Implantation ,Mastectomy ,Retrospective Studies ,business.industry ,Incidence ,Tissue Expansion Devices ,Surgery ,Seroma ,Patient Satisfaction ,030220 oncology & carcinogenesis ,Drainage ,Female ,Implant ,business ,Breast reconstruction ,Support matrix ,Follow-Up Studies - Abstract
BACKGROUND The AlloX2 Breast Tissue Expander (Sientra, Santa Barbara, Calif.) is a unique device that contains a second port to allow for transdermal communication with the pocket around the implant. The injection dome of this expander contains two ports; one is used for traditional saline injection, and a new second port facilitates fluid drainage from the periprosthetic space through an integral drain. The AlloX2 allows for the treatment of seromas and diagnostic fluid sampling to identify bacteria and hone antibiotic treatment in the setting of periprosthetic infection. This device has a significant advantage over traditional expanders, given that seromas and infections are the most common complications in implant-based breast reconstruction, with or without the use of soft-tissue support matrix. METHODS This article provides short-term case studies and surgical pearls from 3 surgeons who utilize the AlloX2 in primary breast reconstruction patients. Three surgeons implanted 40 primary reconstruction patients with AlloX2. Follow-up was approximately 6 months, per the standard of care. All patients implanted with AlloX2 underwent immediate reconstruction, with the exception of 1 delayed reconstruction. RESULTS The most common complications the patients experienced were seromas. In most cases, the surgeons successfully used the second port to drain periprosthetic fluid. CONCLUSIONS The AlloX2 has been successful in treating seromas and should be considered a tool for noninvasive treatment of common complications of implant-based breast reconstruction. Three surgeons with varied backgrounds and techniques provide their surgical and postoperative management experiences and recommendations.
- Published
- 2018
9. Long-Term Safety of Textured and Smooth Breast Implants
- Author
-
Troy A. Pittman, Kamakshi R. Zeidler, Robert E. Cohen, M. Bradley Calobrace, Michael R Schwartz, and W. Grant Stevens
- Subjects
Risk ,medicine.medical_specialty ,business.industry ,Breast Implants ,Ki-1+ Anaplastic Large Cell Lymphoma ,Breast Neoplasms ,General Medicine ,030230 surgery ,law.invention ,Time ,03 medical and health sciences ,0302 clinical medicine ,law ,030220 oncology & carcinogenesis ,Breast implant ,Medicine ,Humans ,Lymphoma, Large-Cell, Anaplastic ,Surgery ,Medical physics ,Female ,Long term safety ,Implant ,business - Abstract
In this review, the authors provide a 20-year review and comparison of implant options and describe the evolution of breast implant surface textures; compare available implant surfaces; present long-term safety data from the 10-year US-based Core clinical studies; list the key benefits and risks associated with smooth and textured implants; and provide perspectives on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The authors explore the key benefits and risks associated with all available devices so that optimal and safe patient outcomes can be achieved.
- Published
- 2017
10. Abstract: Results of the XPAND II Multi-Center, Prospective Clinical Trial for the AeroForm Tissue Expander System used for Two-Stage Breast Reconstruction
- Author
-
Tracey Stokes, Yoon S. Chun, Jeffrey A. Ascherman, Khashayar Mohebali, John Castle, Laura A. Sudarsky, Amy S. Colwell, Kamakshi R. Zeidler, Kerry A. Morrison, and James Appel
- Subjects
Tissue expander ,medicine.medical_specialty ,business.industry ,PSTM 2017 Abstract Supplement ,lcsh:Surgery ,lcsh:RD1-811 ,Breast Session 3 ,030230 surgery ,Surgery ,Sunday, October 8, 2017 ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,Center (algebra and category theory) ,Stage (cooking) ,business ,Breast reconstruction - Published
- 2017
11. Eight-Year Follow-Up Data from the U.S. Clinical Trial for Sientra's FDA-Approved Round and Shaped Implants with High-Strength Cohesive Silicone Gel
- Author
-
Kamakshi R. Zeidler, Kaveh Alizadeh, Tess B. Godinez, Jennifer L. Harrington, David Broadway, and W. Grant Stevens
- Subjects
Adult ,Reoperation ,medicine.medical_specialty ,Adolescent ,Breast Implants ,Prosthesis Design ,law.invention ,Silicone Gels ,Food and drug administration ,Young Adult ,chemistry.chemical_compound ,Patient satisfaction ,Silicone ,law ,Implant Capsular Contracture ,Humans ,Medicine ,Adverse effect ,Breast Implantation ,Aged ,Rupture ,business.industry ,General Medicine ,Capsular contracture ,Middle Aged ,United States ,Prosthesis Failure ,Surgery ,Clinical trial ,chemistry ,Patient Satisfaction ,Premarket Approval Application ,Breast implant ,Female ,business ,Follow-Up Studies - Abstract
Background On March 9, 2012, the Food and Drug Administration (FDA) approved Sientra's premarket approval application for its portfolio of silicone gel breast implants based on their review of Sientra's 3-year study data from the largest pivotal silicone gel breast implant study to date. This included the first approval of shaped breast implants in the United States. Objectives The authors provide an update to the 8-year safety and effectiveness of the Sientra High-Strength silicone gel breast implants. Methods The Sientra Core study is an ongoing 10 year open-label, prospective, multi-center clinical study, which includes 1788 patients implanted with 3506 Sientra implants across four indications (Primary Augmentation, Revision Augmentation, Primary Reconstruction, and Revision Reconstruction). For the safety analysis, the incidence of post-operative complications, including all breast implant–related adverse effects (eg, infection, asymmetry), was estimated based on Kaplan-Meier risk rates. The effectiveness analyses include surgeon and patient satisfaction and changes in bra/cup size. Results Through 8 years, the overall risk of rupture was 4.6%, the risk of capsular contracture was 11.8% (rates were lower when using True Texture™), and the risk of reoperation was 28.3%. Out of the 580 reoperations in 456 patients, over half of all reoperations were due to cosmetic reasons (n = 299). The most common reasons for reoperation were capsular contracture (19.0%), style and/or size change (18.4%), and asymmetry (8.8%). Patient satisfaction remains high through 8 years, with 87% indicating that their breast implants make them feel more feminine than prior to enrollment. Conclusions Safety data from the FDA Core study continues to support a comprehensive safety and effectiveness profile of Sientra's portfolio of round and shaped implants through 8 years. Level of Evidence 3![Graphic][1] Therapeutic [1]: /embed/inline-graphic-1.gif
- Published
- 2015
12. AeroForm Patient Controlled Tissue Expansion and Saline Tissue Expansion for Breast Reconstruction
- Author
-
Yoon S. Chun, Amy S. Colwell, Debra Johnson, Jeffrey A. Ascherman, Donald Morris, Kamakshi R. Zeidler, R. Laurence Berkowitz, Kaveh Alizadeh, Ankit R. Desai, John Castle, Evans G, and Scott T. Hollenbeck
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Breast Implants ,medicine.medical_treatment ,Tissue Expansion ,Sodium Chloride ,law.invention ,Young Adult ,Bolus (medicine) ,Randomized controlled trial ,law ,Outcome Assessment, Health Care ,Humans ,Medicine ,Prospective Studies ,Breast Implantation ,Saline ,Aged ,Tissue expander ,Breast tissue ,business.industry ,Tissue Expansion Devices ,Carbon Dioxide ,Middle Aged ,Surgery ,Implant placement ,Female ,business ,Breast reconstruction ,Tissue expansion - Abstract
BACKGROUND Prosthetic reconstruction of the breast, as a 2-staged procedure using tissue expanders followed by placement of permanent implants, offers favorable aesthetic results with minimal additional surgical intervention. However, the current outpatient process to fill saline expanders can be lengthy and onerous, involving months of office visits and discomfort from the bolus saline expansions. We present a new technology (AeroForm Tissue Expansion System), which has the potential to improve the process of breast tissue expansion by providing a method for low-volume incremental filling, eliminating the need for injections and directly involving the patient by allowing her some control over the expansion process. METHODS The described study is a 2:1 randomized controlled trial of the investigational CO2 expansion system and saline expanders. Of the 82 women receiving expanders, 58 (39 bilateral and 19 unilateral; bilateral rate, 67%) were implanted with CO2 tissue expanders and 24 subjects (15 bilateral and 9 unilateral; bilateral rate, 63%) were implanted with saline expanders. RESULTS Preliminary validated expansion results were available for 55 women. Available mean time for active expansion in the CO2 group was 18.2 (9.2) days (median, 14.0; range, 5-39; number of expanders, 53), which was less than the mean time for active expansion in the saline group: 57.4 (33.6) days (median, 55; range, 5-137; number of expanders, 33). Available mean time from implant placement to exchange for a permanent prosthesis in the CO2 group was shorter [106.3 (42.9) days; median, 99; range, 42-237; number of expanders, 53] than for the women in the control group [151.7 (62.6) days; median, 140; range, 69-433; number of expanders, 33]. After 2 events--underexpansion (n=1) and erosion (n=1)--in the CO2 group, the internal membrane was redesigned and the expander bulk was decreased to minimize the risk of underexpansion and erosion in subsequent patients. CONCLUSIONS Preliminary evidence indicates that the CO2-based tissue expansion system performs the same function as saline expansion devices without significantly altering the risk to the patient and that the device has the potential to make the expansion process faster and more convenient for both the patient and the physician.
- Published
- 2014
13. Response to 'Comments on ‘Long-Term Safety of Textured and Smooth Breast Implants’ and a Plea to Abandon the Use of the MAUDE Database'
- Author
-
Michael R Schwartz, Robert E. Cohen, Troy A. Pittman, Kamakshi R. Zeidler, M. Bradley Calobrace, and W. Grant Stevens
- Subjects
medicine.medical_specialty ,Breast implantation ,business.industry ,Breast Implants ,MEDLINE ,General Medicine ,030230 surgery ,03 medical and health sciences ,0302 clinical medicine ,Plea ,medicine ,Surgery ,Medical physics ,Breast ,Long term safety ,business ,Breast Implantation - Published
- 2018
14. Teaching Core Competencies of Reconstructive Microsurgery With the Use of Standardized Patients
- Author
-
Gordon K. Lee, Leo R. Otake, Michael Ahdoot, Kamakshi R. Zeidler, Ji Son, and Anthony Echo
- Subjects
Microsurgery ,Medical education ,business.industry ,education ,Graduate medical education ,Core competency ,Internship and Residency ,Plastic Surgery Procedures ,Reconstructive microsurgery ,Humans ,Medicine ,Surgery ,Clinical Competence ,Head and neck ,business ,Physical Examination ,health care economics and organizations ,Accreditation - Abstract
The Accreditation Council of Graduate Medical Education has defined 6 core competencies that residents must master before completing their training. Objective structured clinical examinations (OSCEs) using standardized patients are effective educational tools to assess and teach core competencies. We developed an OSCE specific for microsurgical head and neck reconstruction. Fifteen plastic surgery residents participated in the OSCE simulating a typical new patient consultation, which involved a patient with oral cancer. Residents were scored in all 6 core competencies by the standardized patients and faculty experts. Analysis of participant performance showed that although residents performed well overall, many lacked proficiency in systems-based practice. Junior residents were also more likely to omit critical elements of the physical examination compared to senior residents. We have modified our educational curriculum to specifically address these deficiencies. Our study demonstrates that the OSCE is an effective assessment tool for teaching and assessing all core competencies in microsurgery.
- Published
- 2013
15. Transverse Tensor Fascia Lata Myocutaneous Flap for Microvascular Breast Reconstruction
- Author
-
Joseph N. Carey, Kamakshi R. Zeidler, Gordon K. Lee, Oscar H. Ho, Andrew J. Watt, and Ji Son
- Subjects
Adult ,musculoskeletal diseases ,medicine.medical_specialty ,Mammaplasty ,Bilateral mastectomy ,Thigh ,Fascia lata ,Fascia Lata ,medicine ,Humans ,Tensor fascia lata myocutaneous flap ,Thigh surgery ,business.industry ,Thigh lift ,musculoskeletal system ,Myocutaneous Flap ,eye diseases ,Surgery ,body regions ,medicine.anatomical_structure ,Microvessels ,Female ,Breast reconstruction ,business - Abstract
The transverse tensor fascia lata (TTFL) flap is an important alternative flap for autologous breast reconstruction. It is a horizontal variant of the tensor fascia lata myocutaneous flap and contains fat from the prominence of the upper lateral thigh (saddle bag). We present the surgical management of a woman with trochanteric lipodystrophy, who underwent staged bilateral mastectomy and autologous breast reconstruction with TTFL flaps. We discuss technical points in TTFL flap design and harvest. Breast reconstruction was successful and the thigh donor sites had excellent aesthetic contour. There were no complications at either recipient or donor sites. The TTFL flap is an important alternative flap for autologous breast reconstruction when other options are less optimal, and has a secondary benefit of thigh donor site closure with lateral thigh lift techniques. The TTFL flap should be presented as an option for autologous breast reconstruction in women with prominent trochanteric lipodystrophy of the upper lateral thighs.
- Published
- 2013
16. The Matrix Rib Plating System
- Author
-
Kamakshi R. Zeidler, Ji Son, Isaac Saadian, Anthony Echo, Leo R. Otake, Michael Ahdoot, and Gordon K. Lee
- Subjects
medicine.medical_specialty ,Esthetics ,Mammaplasty ,Free flap breast reconstruction ,Ribs ,Free flap ,Prosthesis Design ,Bone plate ,medicine ,Humans ,Breast ,Prospective Studies ,Prospective cohort study ,Retrospective Studies ,Pain, Postoperative ,business.industry ,Soft tissue ,Retrospective cohort study ,Middle Aged ,Rib resection ,Surgery ,Treatment Outcome ,Microvessels ,Female ,Radiology ,business ,Breast reconstruction ,Bone Plates - Abstract
Introduction During microvascular breast reconstruction, exposure of internal mammary vessels (IMVs) is facilitated by the removal of a portion of the rib resulting in occasional chest contour deformity (CCD). The use of rib plating may reduce CCD and reduce postoperative pain. Methods All patients underwent microvascular breast reconstruction using IMVs. In the retrospective arm, photographs were assessed by a blinded reviewer for CCDs. In the prospective cohort, patients were randomized to rib plating with the Synthes Matrix Rib Plating System or no rib plating. Postoperatively, patients were assessed for CCD and pain. Results In the retrospective arm, 11 of 98 (11.2%) patients representing 12 of 130 (9.2%) breast reconstructions had a noticeable contour deformity. The average body mass index (BMI) of patients with CCDs was 26.6 kg/m. In the prospective arm, there was 16% (3 of 19) rate of visible and palpable CCDs among controls, compared to 0% rate of palpable and visible contour deformity in the rib plating group. Pain was decreased in the rib plating group on all postoperative days. The pain reduction was statistically significant at rest by postoperative day 30. Conclusion The majority of patients (9 of 11) with compromised aesthetic outcomes had a BMI less than 30 kg/m, suggesting a paucity of overlying soft tissue contributed to visibility of these bony defects. Rib plating prevented chest contour deformity, reduced postoperative pain, and added limited additional morbidity. We believe that rib plating is a safe, useful adjunct to microvascular breast reconstruction using IMVs, as it may improve aesthetic outcomes and reduce postoperative pain.
- Published
- 2013
17. Nine-Year Core Study Data for Sientra's FDA-Approved Round and Shaped Implants with High-Strength Cohesive Silicone Gel
- Author
-
M. Bradley Calobrace, Kamakshi R. Zeidler, Rosalyn C d'Incelli, Jennifer L. Harrington, W. Grant Stevens, and Kaveh Alizadeh
- Subjects
Adult ,medicine.medical_specialty ,Time Factors ,Adolescent ,Breast Implants ,Kaplan-Meier Estimate ,030230 surgery ,Prosthesis Design ,Risk Assessment ,Silicone Gels ,03 medical and health sciences ,chemistry.chemical_compound ,Patient safety ,Young Adult ,0302 clinical medicine ,Silicone ,Patient satisfaction ,Risk Factors ,Implant Capsular Contracture ,Device Approval ,Medicine ,Humans ,Prospective Studies ,Adverse effect ,Prospective cohort study ,Breast Implantation ,Aged ,Core (anatomy) ,business.industry ,General Medicine ,Capsular contracture ,Middle Aged ,Magnetic Resonance Imaging ,United States ,Surgery ,Treatment Outcome ,chemistry ,Patient Satisfaction ,030220 oncology & carcinogenesis ,Female ,Patient Safety ,business ,Follow-Up Studies - Abstract
Background Since approval in March 2012, data on Sientra's (Santa Barbara, CA) silicone gel implants have been updated and published regularly to provide immediate visibility to the continued safety and performance of these devices. The 9 year follow-up data support the previously published data confirming the ongoing safety and efficacy of Sientra silicone gel breast implants. Objectives The authors provide updated 9 year study data for Sientra's round and shaped silicone gel breast implants. Methods The Core Study is an ongoing 10 year study that enrolled 1788 patients with 3506 Sientra implants across four indications (primary augmentation, revision-augmentation, primary reconstruction, and revision-reconstruction). For the safety analysis, Kaplan-Meier risk rates were calculated to evaluate postoperative complications, including all breast implant–related adverse effects. For the effectiveness analyses, results were presented through 8 years as patient satisfaction scores were assessed at even years. Results Through 9 years, the overall risk of capsular contracture was 12.6%. Smooth devices (16.6%, 95% CI, 14.2%, 19.5%) had a statistically significantly higher rate of capsular contracture compared to textured devices (8.0%, 95% CI, 6.2%, 10.4%). Out of the 610 reoperations in 477 patients, over half of all reoperations were due to cosmetic reasons ( n = 315; 51.6%). Patient satisfaction remains high through 8 years, with 90% of primary augmentation patients indicating their breast implants look natural and feel soft. Conclusions The 9-year follow-up data from the ongoing Core Study of the Sientra portfolio of HSC and HSC+ silicone gel breast implants reaffirm the very strong safety profile as well as continued patient satisfaction. Level of Evidence 2 ![Graphic][1] Therapeutic [1]: /embed/inline-graphic-1.gif
- Published
- 2016
18. Evaluating the Feasibility of Extended Partial Mastectomy and Immediate Reduction Mammoplasty Reconstruction as an Alternative to Mastectomy
- Author
-
Edward I-Fei Chang, Cheryl Ewing, Kamakshi R. Zeidler, Robert D. Foster, Anne Warren Peled, Cheryl Lin, Michael Alvarado, Laura J. Esserman, and E. Shelley Hwang
- Subjects
medicine.medical_specialty ,business.industry ,Mammaplasty ,medicine.medical_treatment ,Lobular carcinoma ,Cosmesis ,Breast Neoplasms ,Middle Aged ,Ductal carcinoma ,Mastectomy, Segmental ,medicine.disease ,Reduction Mammoplasty ,Surgery ,medicine ,Feasibility Studies ,Humans ,Female ,Stage (cooking) ,Breast reconstruction ,business ,Mastectomy ,Retrospective Studies - Abstract
Objectives To assess the efficacy of using concurrent partial mastectomy and reduction mammoplasty for resection of a wide range of tumor sizes and compare oncologic outcomes and postoperative complications on the basis of tumor size. Background Although tumor size greater than 4 cm has been considered an indication for undergoing a mastectomy, this dictum may not apply in women with breast hypertrophy, where the ratio of tumor size to breast size may still permit breast conservation. We wished to evaluate whether an approach combining partial mastectomy with reduction mammoplasty could provide a safe oncologic procedure with immediate breast reconstruction that could technically be applied even for large (>4 cm) lesions. Methods A retrospective review of all patients undergoing partial mastectomy and concurrent reduction mammoplasty performed at our institution from 2000 to 2009. Clinical characteristics at presentation, pathologic data, and follow-up data were collected and analyzed. Results Eighty-five consecutive simultaneous partial mastectomy/reduction mammoplasty procedures were performed in 79 patients. Average tumor size was 2.8 cm for ductal carcinoma in situ (0.05-17.0 cm), 2.4 cm for invasive ductal carcinoma (IDC) (0.2-8.9 cm), 3.5 cm for lobular carcinoma (1.6-8.0 cm), and 5.7 cm for phyllodes tumors (3.7-7.6 cm). Twenty-five of 85 tumors (29.4%) were larger than 4 cm. Distribution for stage 0, I, II, III, and IV disease was 15, 12, 35, 19, and 2 tumors respectively, with an additional 2 phyllodes tumors. Median follow-up was 39 months (10-130 months). Seventy-five patients (94.9%) achieved successful breast conservation, whereas 4 patients (5.1%) went on to completion mastectomy. Thirteen patients (16.4%) required 1 reexcision to achieve clear margins, and 2 (2.5%) required multiple reexcisions. Two patients had a local recurrence during the follow-up period, one of whom underwent reexcision and the other underwent mastectomy. The overall complication rate was 14.1%, which included 4 major complications (4.7%) requiring an unplanned return to the operating room and need for hospital readmission, and 8 minor wound-related complications (9.4%). Neither recurrence nor complication rates were increased in patients with tumors greater than 4 cm when compared with tumors less than or equal to 4 cm. Conclusions A partial mastectomy with concurrent reduction mammoplasty technique is a viable option for breast conservation even for larger tumors, combining a safe oncologic procedure with excellent cosmesis. A combined effort between breast surgeons and reconstructive surgeons has a high probability of success with low recurrence rates. In carefully selected patients, this approach may be preferable to mastecomy and breast reconstruction, particularly when postmastectomy radiation therapy is anticipated.
- Published
- 2012
19. Carbon Dioxide versus Saline Tissue Expanders: Does It Matter?
- Author
-
Amy S. Colwell, Debra Johnson, James Appel, Adam Jacoby, Kamakshi R. Zeidler, Yoon S. Chun, John Castle, R. Laurence Berkowitz, Khashayar Mohebali, and Jeffrey A. Ascherman
- Subjects
Adult ,Graft Rejection ,medicine.medical_specialty ,Percutaneous ,medicine.medical_treatment ,Breast Implants ,Tissue Expansion ,Breast Neoplasms ,030230 surgery ,Sodium Chloride ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Risks and benefits ,Saline ,Breast Implantation ,Mastectomy ,Aged ,Tissue expander ,business.industry ,Graft Survival ,Tissue Expansion Devices ,Carbon Dioxide ,Middle Aged ,Surgery ,Plastic surgery ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Implant ,business ,Breast reconstruction ,Tissue expansion ,Follow-Up Studies - Abstract
Background Implant-based breast reconstruction is the most common reconstructive technique in the United States. Despite its popularity, saline-based tissue expansion still has its limitations, including lengthy expansion times, large uncomfortable bolus dosing, and frequent percutaneous injections/expansion visits. Ideally, a novel technology would eliminate frequent, percutaneous saline injections and allow patients to perform expansion at home, reducing the disruptive experience of current tissue expansion. Methods Within the past 6 years, the AeroForm tissue expander system has used remotely activated carbon dioxide release as the fill medium instead of saline, eliminating many limitations of traditional tissue expanders. In this article, the authors first review the relevant literature concerning carbon dioxide-based tissue expansion in animal and human models. The authors then analyze the similarities and differences between two groundbreaking human trials (i.e., Patient Activated Controlled Expansion and AirXpanders Patient Activated Controlled Tissue Expander) with carbon dioxide-based expanders and discuss the risks and benefits associated with this new technology. Results At their site, the authors have enrolled 34 patients using 36 experimental devices in total, and have found significantly shorter expansion and overall reconstruction times in the patient-controlled tissue expander group. Conclusions The authors believe that carbon dioxide-based devices may play a significant role in the future of implant-based breast reconstruction, and may be widely applicable to other areas of plastic surgery that also involve tissue expansion.
- Published
- 2015
20. Desmopressin as a hemostatic agent to provide a dry intraoperative field in rhinoplasty
- Author
-
Ronald P. Gruber, R. Laurence Berkowitz, and Kamakshi R. Zeidler
- Subjects
Adult ,Male ,medicine.medical_specialty ,Vasopressin ,Adolescent ,medicine.medical_treatment ,Blood Loss, Surgical ,Hemostatics ,Rhinoplasty ,Young Adult ,Blood loss ,Medicine ,Humans ,Deamino Arginine Vasopressin ,Adverse effect ,Lead (electronics) ,Desmopressin ,Aged ,Retrospective Studies ,Hemostatic Agent ,Intraoperative Care ,Dose-Response Relationship, Drug ,business.industry ,Hemostatic Techniques ,Retrospective cohort study ,Middle Aged ,Surgery ,Anesthesia ,Female ,business ,medicine.drug ,Follow-Up Studies - Abstract
Background Intraoperative bleeding during rhinoplasty makes it difficult to sculpt cartilages. Residual blood from a wet field can lead to induration, fibrosis, and definition loss. Recent studies with desmopressin (1-deamino-8-D-arginine vasopressin) to reduce blood loss in a variety of operations and minimize postoperative bleeding problems suggest using that drug routinely for elective rhinoplasty and not just for patients with coagulation issues. Method Seventy-three consecutive rhinoplasty patients received desmopressin for the purpose of obtaining a dry operative field. The initial dose was 0.1 μg/kg. If the field was not as dry as desired, a second dose was given; if necessary, a third dose to a maximum of 0.3 μg/kg was given. All cases exhibited a satisfactorily dry field. There were no adverse effects. A retrospective comparison was made to 300 consecutive cases not receiving desmopressin. Results Thirty of the 73 patients received a starting dose of 0.1 μg/kg and nothing more. Fourteen received a second dose of 0.1 μg/kg because the field was not as dry as desired and 29 received a third dose of 0.1 μg/kg because the field was not as dry as desired. All 73 patients exhibited a satisfactorily dry field, in contrast to 9 percent in the group not receiving desmopressin. Conclusions This study confirms the hemostatic effectiveness of desmopressin at lower than normally used doses in rhinoplasty. It also confirms its safety. It suggests its use in other procedures. A larger, carefully controlled study is indicated. Clinical question/level of evidence Therapeutic, III.
- Published
- 2015
21. XPAND Patient-Activated Controlled Tissue Expander System for Breast Reconstruction
- Author
-
Amy S. Colwell, Debra Johnson, R. Laurence Berkowitz, Scott T. Hollenbeck, Khashayar Mohebali, Brian Thornton, Kamakshi R. Zeidler, Aldona J. Spiegel, John Castle, Yoon S. Chun, Donald Morris, Gregory R. D. Evans, Jeffrey A. Ascherman, Susan E. Downey, James Appel, Ankit R. Desai, and Kaveh Alizadeh
- Subjects
Clinical trial ,Tissue expander ,medicine.medical_specialty ,business.industry ,Medicine ,Surgery ,Center (algebra and category theory) ,Radiology ,Breast reconstruction ,business - Published
- 2014
22. Abstract
- Author
-
Yoon S. Chun, Amy S. Colwell, R. Laurence Berkowitz, Debra Johnson, James Appel, Khashayar Mohebali, John Castle, Kamakshi R. Zeidler, Kerry A. Morrison, and Jeffrey A. Ascherman
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,Surgery ,Radiology ,Stage (cooking) ,business ,Breast reconstruction - Published
- 2016
23. Microsurgery education in residency training: validating an online curriculum
- Author
-
Gordon K. Lee, James Chang, Kamakshi R. Zeidler, Thomas Satterwhite, Sina Bari, Ji Son, Geoffrey C. Gurtner, and Joseph N. Carey
- Subjects
Self-assessment ,Adult ,Male ,Microsurgery ,Self-Assessment ,Teaching method ,medicine.medical_treatment ,education ,California ,Patient safety ,Medicine ,Humans ,Computer Simulation ,Surgery, Plastic ,Curriculum ,Medical education ,Analysis of Variance ,Internet ,business.industry ,Internship and Residency ,Test (assessment) ,Education, Medical, Graduate ,Test score ,Surgery ,Clinical Competence ,Apprenticeship ,business - Abstract
Introduction Plastic surgery training has traditionally been modeled as an "apprenticeship," where faculty teach surgical skills to residents on live patients. Although this is a well-established process, the demand by the public and healthcare agencies for improved patient care, outcomes, and patient safety has led to the development of adjunct methods of teaching. The goal of this project is to assess the effectiveness of a web-based microsurgical curriculum. Methods We developed an interactive Web site to teach essential microsurgical competencies. Residents were randomly divided into 2 cohorts: one experimental group completed this online resource and the other control group did not. Pre- and postassessments were administered, consisting of a written test and a recorded microsurgery skills session. Results A total of 17 plastic surgery residents of various training levels participated in the study. Residents who completed the web-based curriculum showed dramatic improvement in their knowledge and skills, with a 17-percentage point increase in their test scores (P = 0.01) compared with controls (P = 0.80). The experimental group was more likely to perform microanastomoses faster with an average of 4.5-minute improvement compared with 1.25-minute change among the control group. Residents performed self-assessments, and those who rated themselves as "very confident" had higher overall test scores (85% test score vs. 59%, P = 0.004), as well as shorter times to complete the microsurgical task (7.5 minutes vs. 13.6 minutes, P = 0.007). Overall, 62% of residents rated the online webpage as extremely valuable. The majority of residents reported the webpage improved their knowledge and markedly improved their microsurgical technique, which was confirmed by faculty experts. Conclusions Our interactive Web-based curriculum is a novel resource, teaching microsurgery in an organized, competency-based manner, which we believe is the first Web site of this nature. An individualized, self-paced Web site is ideal for plastic surgery trainees of all levels. Overall, the widespread implementation of our proposed curriculum--online self-directed training combined with regular practice sessions--will establish a strong foundation of microsurgery knowledge and skills acquisition for all plastic surgery residents.
- Published
- 2012
24. Abstract 10
- Author
-
Yoon S. Chun, Ankit R. Desai, Aldona J. Spiegel, Amy S. Colwell, Scott T. Hollenbeck, Kaveh Alizadeh, Kamakshi R. Zeidler, Debra Johnson, Susan E. Downey, James Appel, Greg R. D. Evans, Jeffrey A. Ascherman, John Castle, Khashayar Mohebali, Brian Thornton, R. Laurence Berkowitz, and Dan Morris
- Subjects
Tissue expander ,medicine.medical_specialty ,business.industry ,Medicine ,Surgery ,business ,Breast reconstruction - Published
- 2014
25. Experience with Free Fibula Peroneal Osteofascial Flap for Composite Head and Neck Reconstruction
- Author
-
Pablo Leon, Kamakshi R. Zeidler, Edward I. Chang, and Brian L. Schmidt
- Subjects
medicine.medical_specialty ,Free fibula ,business.industry ,medicine ,Surgery ,business ,Head and neck - Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.